Učitavanje...
Simvastatin Reduces Circulating Plasminogen Activator Inhibitor 1 Activity in Volunteers with the Metabolic Syndrome
BACKGROUND: The Metabolic Syndrome (MS) confers an increased risk for diabetes and cardiovascular disease. We previously showed that simvastatin has concomitant benefits in reducing low-density lipoprotein (LDL)–cholesterol and inflammation in MS subjects. The levels of plasminogen activator inhibit...
Spremljeno u:
| Glavni autori: | , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Mary Ann Liebert, Inc.
2008
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2692921/ https://ncbi.nlm.nih.gov/pubmed/18484901 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/met.2008.0012 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|